Powis G - Search Results

1

Thioredoxin signaling as a target for cancer therapy.

Powis G, Kirkpatrick DL. Powis G, et al. Curr Opin Pharmacol. 2007 Aug;7(4):392-7. doi: 10.1016/j.coph.2007.04.003. Epub 2007 Jul 3. Curr Opin Pharmacol. 2007. PMID: 17611157 Review.

2

The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.

Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu CH, Kirkpatrick DL, Powis G. Baker AF, et al. Among authors: powis g. J Lab Clin Med. 2006 Feb;147(2):83-90. doi: 10.1016/j.lab.2005.09.001. J Lab Clin Med. 2006. PMID: 16459166 Free PMC article. Clinical Trial.

3

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.

Powis G, Wipf P, Lynch SM, Birmingham A, Kirkpatrick DL. Powis G, et al. Mol Cancer Ther. 2006 Mar;5(3):630-6. doi: 10.1158/1535-7163.MCT-05-0487. Mol Cancer Ther. 2006. PMID: 16546977 Free PMC article.

4

Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues.

Oblong JE, Chantler EL, Gallegos A, Kirkpatrick DL, Chen T, Marshall N, Powis G. Oblong JE, et al. Among authors: powis g. Cancer Chemother Pharmacol. 1994;34(5):434-8. Cancer Chemother Pharmacol. 1994. PMID: 8070012

5

Selenium and the thioredoxin redox system: effects on cell growth and death.

Powis G, Gasdaska JR, Gasdaska PY, Berggren M, Kirkpatrick DL, Engman L, Cotgreave IA, Angulo M, Baker A. Powis G, et al. Oncol Res. 1997;9(6-7):303-12. Oncol Res. 1997. PMID: 9406236 Review.

6

Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.

Kunkel MW, Kirkpatrick DL, Johnson JI, Powis G. Kunkel MW, et al. Among authors: powis g. Anticancer Drug Des. 1997 Dec;12(8):659-70. Anticancer Drug Des. 1997. PMID: 9448705

7

Thioredoxin redox control of cell growth and death and the effects of inhibitors.

Powis G, Kirkpatrick DL, Angulo M, Baker A. Powis G, et al. Chem Biol Interact. 1998 Apr 24;111-112:23-34. doi: 10.1016/s0009-2797(97)00148-8. Chem Biol Interact. 1998. PMID: 9679540 Review.

8

Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.

Kirkpatrick DL, Powis G. Kirkpatrick DL, et al. Among authors: powis g. Antioxid Redox Signal. 2017 Feb 20;26(6):262-273. doi: 10.1089/ars.2016.6633. Epub 2016 Apr 22. Antioxid Redox Signal. 2017. PMID: 26983373 Free PMC article. Review.

9

The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.

Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. Welsh SJ, et al. Among authors: powis g. Mol Cancer Ther. 2003 Mar;2(3):235-43. Mol Cancer Ther. 2003. PMID: 12657718

10

Practicalities of drugging the phosphatidylinositol-3-kinase/Akt cell survival signaling pathway.

Powis G, Ihle N, Kirkpatrick DL. Powis G, et al. Clin Cancer Res. 2006 May 15;12(10):2964-6. doi: 10.1158/1078-0432.CCR-06-0617. Clin Cancer Res. 2006. PMID: 16707590 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

363 results

Search Page

Filters